Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

An inv(16) in Ph-negative cells of a chronic myelogenous leukemia patient after imatinib treatment.

Rowe LR, Brothman AR, Nibley WE, Gaffney MR, Chen Z

Institute for Clinical and Experimental Pathology, Associated Regional and University Pathologists (ARUP) Laboratories, 500 Chipeta Way, Salt Lake City, UT 84108-1221, USA. rowelr@aruplab.com

Secondary chromosomal changes are known to develop in Philadelphia chromosome-negative (Ph-) cells of chronic myelogenous leukemia (CML) patients after treatment with imatinib mesylate, an ABL kinase inhibitor. We report here a novel case of a pericentric inversion of chromosome 16 as the sole cytogenetic abnormality in Ph- cells after treatment of Ph+ CML with imatinib.

Published 12 March 2007 in Cancer Genet Cytogenet, 174(1): 54-6.
Full-text of this article is available online (may require subscription).

© 2004-2008 Glivec Research Today. All Rights Reserved.